Essential thrombocythemia is a rare disease in which your body produces excessive blood platelets. Platelets also called thrombocytes are the blood cells responsible for blood clotting. Human blood contains platelets in the range of 150,000 to 450,000 per microliter. Essential thrombocythemia occurs due to mutation in JAK2, CALR genes.
These mutations lead to abnormal hyperactive signalling of a pathway called JAK pathway. Leading to Essential thrombocythemia. Gene mutations in Essential thrombocythemia are somatic mutations and occur in initial blood forming cells. People with Essential thrombocythemia experience abnormal blood clotting. The abnormal blood clotting is called thrombosis.
Clots can also move to lungs causing chest pain and difficulty in breathing. Thrombosis can occur in legs leading to leg pain. People with Essential thrombocythemia may experience abnormal bleeding in the form of nosebleeds, bleeding gums or bleeding within gastrointestinal tract.
Essential thrombocythemia market: Drivers and restraints
Essential thrombocythemia has a Potential for new treatments under development and many are currently being tested. This is the major factor contributing to its market growth. Essential thrombocythemia is more common in people above age of 50 years. Essential thrombocythemia affects around 1 to 24 per 1 million people worldwide. . Gaining popularity of drugs like Aspirin for the patients is the major driving force. Increasing prevalence amongst pediatric population also create opportunity for market players in the Essential thrombocythemia treatment market
The rate of occurrence of essential thrombocythemia in women is 1.5 times higher than men. Increase in prevalence rate of Essential thrombocythemia across the world and increase in geriatric population worldwide and ongoing research and development for Essential thrombocythemia treatment can be major drivers for growth of this market. However, cost of the diagnosis especially genetic screening is a major setback for its market growth. These kind of rare diseases are tend to be neglected by people especially in the lower economic regions. The incidence and prevalence of Essential thrombocythemia is increasing in certain populations but the fatality rate is low.
Currently, with the escalation of COVID-19 pandemic, the healthcare systems are affected worldwide, and a rare disease like Essential thrombocythemia is likely to be neglected. This can affect patients worldwide.
Essential thrombocythemia market: Segmentation
Based on treatment drug type, Essential thrombocythemia market is segmented into following;
Based on distribution channel global Essential thrombocythemia market is segmented into following
Essential thrombocythemia market: Overview
Drug called IMG-7289 is under phase 2 clinical trial for treatment of Essential thrombocythemia. The gold standard treatment for thrombocythemia is Aspirin. Other Drugs like hydroxyurea, anagrelide and interferon alfa-2b are also popular in the treatment.
The future of essential thrombocythemia treatment scenario has a high chance of gaining an array of novel treatment is anticipated that few novel discoveries will get approvals over the forecast period. Although historically the growth graph of the market has been modest, companies continue to assess novel therapeutic approaches and combination regimens that could potentially improve treatment outcomes. It is expected that Aspirin which is used to treat essential thrombocythemia will show substantial Growth 2026
Essential thrombocythemia market: Region wise outlook
North America is the leader in essential thrombocythemia drug market. With respect to revenue, the U.S. has a major share of the essential thrombocythemia drugs market especially in North America. The essential thrombocythemia drug market is growing rapidly in Europe due to growing geriatric population.
Increasing adoption of novel drugs is the primary reason for growth of the market in the US. Presence of a large target population can also be a growth stimulant for the essential thrombocythemia market in North America.
There is a hope of growth in essential thrombocythemia treatment market in developing countries because of growing health care infrastructure, economic growth advancement, development of the private health care sector. Awareness among people in these countries is increasing regarding such diseases.
Essential thrombocythemia market: Key players
Some of the key market players in Essential thrombocythemia treatment market are Incyte, Bayer AG, USV Pvt Ltd, Teva Pharmaceutical Industries Ltd, Novartis AG, AstraZeneca, Pfizer Inc, Bristol Myers Squibb Company, Shire, Bayer AG, Novacap and Eli Lilly And Company
The research report on Essential thrombocythemia presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report on Essential thrombocythemia provides analysis and information according to market segments such as geographies, application, and industry.
The report covers exhaust analysis on:
Regional analysis includes:
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.